Morgan Stanley cuts Amcor stock price target to $42 on lower earnings

Morgan Stanley cut its price target on Amcor to $42 from $44 while keeping an Equalweight rating, citing lower earnings estimates across fiscal 2026-2028. The firm trimmed EBIT forecasts by 1%-2% and EPS estimates by 1%-2%, though Amcor’s Q3 2026 results were mixed-to-stable with EPS of $0.96 in line and revenue of $5.91 billion above the $5.71 billion consensus. The stock trades at $39.10, near its 52-week low of $36.67.

Analysis

AMCR looks like a slow-burn compounder rather than a near-term catalyst trade: the modest estimate reset tells us the market is still pricing it as a defensive cash-flow name, but not paying for growth optionality. The more important second-order effect is that packaging demand is being treated as a late-cycle proxy, so every small downward revision in EBIT can keep the stock pinned near the low end of its range unless management proves pricing discipline or mix improvement. That makes the stock vulnerable to multiple compression even if headline EPS appears “fine.”

The cleaner signal is on relative value: a lower target with only slight estimate cuts suggests the downside is less about a collapse in fundamentals and more about the absence of a rerating catalyst. In other words, AMCR can drift lower on no news because the market has to underwrite a mid-single-digit growth profile with limited operating leverage. That favors short-dated options selling or relative shorts versus higher-quality defensives if one believes the tape remains risk-off.

For NVDA, the article’s headline is effectively a policy overhang rather than a fundamental shift, but the important implication is inventory and mix: if China access improves even incrementally, it can support demand for older Hopper architecture and reduce pressure to discount excess supply. The market may initially treat this as positive for near-term revenue, but the better read is that it extends the life of prior-gen product and delays some replacement demand into Blackwell, which could cap multiple expansion if investors had been expecting a cleaner upgrade cycle. The main contrarian risk is that the benefit accrues to channel fill and cash conversion first, while margin and mix benefits arrive later.

MS is mostly collateral here: the broader takeaway is that policy headlines are still driving semi beta more than fundamentals. If the China dynamic broadens, expect semicap and networking names with China exposure to move as the second derivative trade, while packaging remains a separate idiosyncratic earnings story with no macro torque.

Key Decisions for Investors

• Hold off on adding AMCR outright for 2-4 weeks; prefer waiting for either a capitulation flush toward the 52-week low or evidence of a stabilization in EBIT guidance, because the stock lacks a rerating catalyst and can bleed lower on estimate revisions.
• If already long AMCR, consider a covered-call overwrite into 30-45 day tenor to monetize elevated idiosyncratic drift risk; downside appears limited but upside is also capped until management proves pricing/mix improvement.
• For NVDA, buy a tactical call spread on any intraday selloff tied to China-policy headlines, with a 1-2 month horizon; the risk/reward favors upside follow-through if traders reprice near-term demand durability without demanding a full re-rating.
• Pair trade: long NVDA / short AMCR over the next 1-3 months; the trade isolates policy-driven semiconductor optionality against a packaging name facing slow estimate erosion and no obvious catalyst.